Corrigendum: relacorilant, a selective glucocorticoid receptor modulator, induces clinical improvements in patients with cushing syndrome: results from a prospective, open-label phase 2 study

HIGHLIGHTS

• who: Rosario Pivonello from the Frontiers Media SA, SwitzerlandNetherlands, Department of Medicine, Division of Endocrinology, Diabetes and Metabolism, University of Miami, Miami, FL have published the Article: Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study, in the Journal: (JOURNAL) of 18/03/2022

SUMMARY

A Corrigendum on Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study By Pivonello R, Bancos I, Feelders RA . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.